FCGR3A and neoplasm: Nanobodies activate NK cells by binding to CD16; sequentially, CD16-mediated antibody-dependent cellular cytotoxicity (ADCC) is initiated to induce cytotoxic effects (nanobodies and nanobody-based human heavy-chain antibodies as anti-tumor therapeutics).